Former Dendreon CEO Gold's New Cell Therapy Business Partners With Kite

With insights into what's needed to make a cell therapy for cancer succeed, former Dendreon Corp. CEO Mitchell Gold is shepherding new technology for closely-watched immunotherapies into the clinic through his latest company Alpine Immune Sciences Inc., which has entered into a $535m-plus partnership with Kite Pharma Inc.